查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571501

NUT 中線癌症治療市場規模、佔有率和趨勢分析報告：2024-2030 年按治療、給藥途徑、最終用途、地區和細分市場進行的預測

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

NUT 中線癌症治療市場成長與趨勢：

Grand View Research, Inc.的研究報告顯示，到2030年，全球NUT中線癌症治療市場規模預計將達到441億美元，複合年成長率為12.4%。

這一顯著成長主要是由於對罕見癌症類型的認知提高、標靶治療的進步以及對精準醫療的日益關注。診斷工具的進步和醫療保健專業人員意識的提高使得更多病例能夠更早被發現，從而導致對有效治療的需求增加。

標靶治療的興起，特別是那些關注表觀遺傳機制的治療，對於這個市場至關重要。例如，針對通常與 NMC 相關的 BRD4-NUT 融合蛋白的 BET（Bromodomain和末端外）抑制劑的開發開闢了新的治療途徑。百時美施貴寶等公司處於這項研究的前沿，開發了 trotabresib (CC-90010) 等藥物，目前正處於臨床試驗階段。由於這種疾病的侵襲性和預後不良，因此迫切需要開發新的治療方法。這種疾病的罕見性也帶來了挑戰，包括臨床試驗的患者數量有限以及缺乏全面的流行病學資料。

政府和監管機構在加速 NMC 治療開發方面也發揮著重要作用。在包括美國和歐洲在內的許多地區，NMC 已被指定為一種罕見疾病，為開發這種罕見癌症治療方法的公司提供稅額扣抵和擴大市場獨佔權等獎勵。這些激勵措施對於鼓勵 NMC 研究投資至關重要，因為 NMC 研究受到患者數量較少的限制。

NUT 中線癌症治療市場報告亮點

  • 2023年，化療市場在NUT中線癌症治療市場中佔最大收益佔有率，達32.5%。
  • 2023年，靜脈注射細分市場將佔最大收益佔有率，達68.7%。這是由於 NMC 管理中對速效治療的需求所驅動的，因為更高的生物有效性和更快地將藥物輸送到血液中可確保有效的治療方法到達癌細胞。比口服藥物更有效。
  • 預計專科診所在預測期內的複合年成長率將達到 13.5%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 NUT 中線癌症治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場成長要素分析
    • 市場限制因素分析
  • NUT 中線癌症治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第 4 章 NUT 中線癌症治療市場：按治療分類的估計和趨勢分析

  • 全球 NUT 中線癌症治療市場：依治療分類 - 儀表板
  • 全球 NUT 中線癌症治療市場：依治療分類 - 波動分析
  • 全球 NUT 中線癌症治療市場：依治療分類-收益
  • 化療
  • 標靶治療
  • 免疫療法
  • 放射治療
  • 其他

第5章 NUT 中線癌症治療市場：依給藥途徑估計與趨勢分析

  • 全球 NUT 中線癌症治療市場：按給藥途徑- 儀表板
  • 全球 NUT 中線癌症治療市場：依給藥途徑- 變異分析
  • 全球 NUT 中線癌症治療市場：按給藥途徑- 收益
  • 口服
  • 靜脈
  • 其他

第6章 NUT 中線癌症治療市場：按最終用途分類的估計和趨勢分析

  • 全球 NUT 中線癌症治療市場：依最終用途分類 - 儀表板
  • 全球 NUT 中線癌症治療市場：依最終用途 - 變化分析
  • 全球 NUT 中線癌症治療市場：依最終用途分類-收益
  • 醫院
  • 專科診所
  • 其他

第7章 NUT中線癌症治療市場：區域估計與趨勢分析

  • 按地區 - 儀表板
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 2023年主要企業市場佔有率分析
    • Merck &Co. Inc
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • C4 Therapeutics, Inc.
    • Ipsen Biopharmaceuticals, Inc
    • GSK plc
Product Code: GVR-4-68040-444-7

NUT Midline Carcinoma Treatment Market Growth & Trends:

The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.

The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.

Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.

NUT Midline Carcinoma Treatment Market Report Highlights:

  • In 2023, the chemotherapy segment accounted for the largest revenue share of 32.5% in NUT midline carcinoma treatment market.
  • The intravenous segment accounts for the largest revenue share of 68.7% in 2023 driven by the need for fast-acting treatments in managing NMC due to its higher bioavailability and quicker delivery of the drug to the bloodstream, ensuring that the potent therapies reach the tumor cells more effectively than oral medications might.
  • Specialty clinics are anticipated to achieve the highest CAGR of 13.5% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. NUT midline carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence NUT Midline Carcinoma
      • 3.2.1.2. Advancement in Diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Diagnostic Challenges
      • 3.2.2.2. Limited Awareness
  • 3.3. NUT midline carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. NUT midline carcinoma Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global NUT midline carcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global NUT midline carcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global NUT midline carcinoma Treatment Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. NUT midline carcinoma Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global NUT midline carcinoma Treatment Market: Route of Administration Dashboard
  • 5.2. Global NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
  • 5.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Intravenous
    • 5.5.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. NUT midline carcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Global NUT midline carcinoma Treatment Market: End Use Dashboard
  • 6.2. Global NUT midline carcinoma Treatment Market: End Use Movement Analysis
  • 6.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other
    • 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. NUT midline carcinoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Merck & Co. Inc
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bristol-Myers Squibb Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Pfizer Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. F. Hoffmann-La Roche Ltd
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. C4 Therapeutics, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Ipsen Biopharmaceuticals, Inc
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. GSK plc
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 4 North America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 North America NUT Midline Carcinoma Treatment Market, End Use, 2018 - 2030 (USD Million)
  • Table 6 U.S. NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 Canada NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 Canada NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 Mexico NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Europe NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 16 Europe NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 19 Germany NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22 UK NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 UK NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 France NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 26 France NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Italy NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Italy NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 Spain NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 32 Spain NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Denmark NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 35 Denmark NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Sweden NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 Sweden NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Sweden NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Norway NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 41 Norway NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Norway NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 47 China NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48 China NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 China NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 50 Japan NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Japan NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Japan NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 53 India NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 54 India NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 India NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 South Korea NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 57 South Korea NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Korea NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 Australia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 Australia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Australia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 Thailand NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 63 Thailand NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Thailand NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Latin America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 66 Latin America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 67 Latin America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 69 Brazil NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 70 Brazil NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Brazil NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 Argentina NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Argentina NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 MEA NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 76 MEA NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 77 MEA NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 MEA NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 79 South Africa NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 South Africa NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 UAE NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 UAE NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Kuwait NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 NUT midline carcinoma Treatment Market: Market Outlook
  • Fig. 14 NUT midline carcinoma Treatment Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 NUT midline carcinoma Treatment Market Driver Impact
  • Fig. 18 NUT midline carcinoma Treatment Market Restraint Impact
  • Fig. 19 NUT midline carcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 20 NUT midline carcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 21 NUT midline carcinoma Treatment Market: Treatment Outlook and Key Takeaways
  • Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 25 Radiation therapy market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
  • Fig. 28 NUT midline carcinoma Treatment Market: Route of Administration Outlook and Key Takeaways
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030
  • Fig. 30 Intravenous market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 NUT midline carcinoma Treatment Market: End Use Movement Analysis
  • Fig. 33 NUT midline carcinoma Treatment Market: End Use Outlook and Key Takeaways
  • Fig. 34 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 35 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 36 Other market estimates and forecast, 2018 - 2030
  • Fig. 37 Global NUT midline carcinoma Treatment Market: Regional Movement Analysis
  • Fig. 38 Global NUT midline carcinoma Treatment Market: Regional Outlook and Key Takeaways
  • Fig. 39 Global NUT midline carcinoma Treatment market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share of key market players- NUT midline carcinoma Treatment market